S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy

Canopy Growth (CGC) Competitors

$7.80
-0.35 (-4.29%)
(As of 04/12/2024 ET)

CGC vs. USNA, MNMD, CRON, BTMD, ACB, CDXC, CRGX, ARCT, QTRX, and LAB

Should you be buying Canopy Growth stock or one of its competitors? The main competitors of Canopy Growth include USANA Health Sciences (USNA), Mind Medicine (MindMed) (MNMD), Cronos Group (CRON), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), CARGO Therapeutics (CRGX), Arcturus Therapeutics (ARCT), Quanterix (QTRX), and Standard BioTools (LAB). These companies are all part of the "medical" sector.

Canopy Growth vs.

USANA Health Sciences (NYSE:USNA) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

54.3% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 0.3% of USANA Health Sciences shares are owned by insiders. Comparatively, 0.4% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

USANA Health Sciences has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

USANA Health Sciences received 375 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 60.77% of users gave USANA Health Sciences an outperform vote while only 19.80% of users gave Canopy Growth an outperform vote.

CompanyUnderperformOutperform
USANA Health SciencesOutperform Votes
395
60.77%
Underperform Votes
255
39.23%
Canopy GrowthOutperform Votes
20
19.80%
Underperform Votes
81
80.20%

In the previous week, Canopy Growth had 8 more articles in the media than USANA Health Sciences. MarketBeat recorded 12 mentions for Canopy Growth and 4 mentions for USANA Health Sciences. USANA Health Sciences' average media sentiment score of 1.02 beat Canopy Growth's score of 0.15 indicating that Canopy Growth is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
USANA Health Sciences
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Canopy Growth
8 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

USANA Health Sciences currently has a consensus price target of $48.00, suggesting a potential upside of 9.17%. Canopy Growth has a consensus price target of $4.87, suggesting a potential downside of 37.61%. Given Canopy Growth's stronger consensus rating and higher probable upside, equities analysts plainly believe USANA Health Sciences is more favorable than Canopy Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
USANA Health Sciences
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Canopy Growth
2 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

USANA Health Sciences has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$921.01M0.92$63.79M$3.3013.32
Canopy Growth$304.79M2.33-$2.48B-$15.12-0.52

USANA Health Sciences has a net margin of 6.93% compared to USANA Health Sciences' net margin of -326.75%. Canopy Growth's return on equity of 13.49% beat USANA Health Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
USANA Health Sciences6.93% 13.49% 10.45%
Canopy Growth -326.75%-73.48%-27.82%

Summary

USANA Health Sciences beats Canopy Growth on 13 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CGC vs. The Competition

MetricCanopy GrowthMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$710.66M$1.31B$4.88B$7.64B
Dividend YieldN/A2.41%2.95%3.92%
P/E Ratio-0.526.97257.0319.38
Price / Sales2.3310.942,401.4395.00
Price / CashN/A177.8137.0731.69
Price / Book0.702.414.614.29
Net Income-$2.48B-$169.93M$103.90M$214.71M
7 Day Performance-23.38%-6.14%-2.32%-2.30%
1 Month Performance181.59%12.83%-0.36%-0.06%
1 Year Performance-45.45%8.26%14.38%8.81%

Canopy Growth Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
USNA
USANA Health Sciences
3.3996 of 5 stars
$47.29
+1.2%
$48.00
+1.5%
-31.9%$909.86M$921.01M14.331,800News Coverage
MNMD
Mind Medicine (MindMed)
1.6246 of 5 stars
$10.05
-7.7%
$24.83
+147.1%
+211.9%$706.21MN/A-4.1057Short Interest ↑
CRON
Cronos Group
1.4673 of 5 stars
$2.67
-1.1%
$2.83
+6.1%
+32.8%$1.02B$87.24M-14.05356Options Volume
BTMD
biote
2.8575 of 5 stars
$6.07
+2.4%
$8.11
+33.6%
+0.0%$452.41M$185.36M-27.59194Short Interest ↑
Positive News
ACB
Aurora Cannabis
0.1884 of 5 stars
$6.36
-9.3%
N/A+0.3%$346.60M$174.88M-2.191,338Gap Down
High Trading Volume
CDXC
ChromaDex
3.8057 of 5 stars
$3.98
-5.5%
$5.87
+47.4%
+161.9%$299.73M$83.57M-56.85106Analyst Report
Short Interest ↑
CRGX
CARGO Therapeutics
0.859 of 5 stars
$21.22
+0.1%
$29.67
+39.8%
N/A$835.28MN/A0.00116Short Interest ↑
News Coverage
ARCT
Arcturus Therapeutics
1.6555 of 5 stars
$31.66
+2.4%
$61.33
+93.7%
+7.4%$832.48M$157.75M-30.44180Short Interest ↑
QTRX
Quanterix
3.0506 of 5 stars
$21.71
+1.8%
$32.00
+47.4%
+33.2%$826.28M$122.37M-25.24441Short Interest ↓
Positive News
Gap Down
LAB
Standard BioTools
2.7611 of 5 stars
$2.92
+1.4%
$3.63
+24.1%
+53.3%$847.15M$106.34M-3.07534Short Interest ↑

Related Companies and Tools

This page (NASDAQ:CGC) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners